Complete Revascularization after Pharmacoinvasive Strategy

Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI.  

Revascularización completa luego de estrategia fármaco invasiva

The COMPLETE showed that staged non-culprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in STEMI patients with multivessel coronary artery disease. This benefit was not clear for patients initially receiving antithrombotic medication not being able to access PCI right away. 

Following successful culprit lesion PCI, STEMI 4041 patients with multivessel disease were randomized to either routine non-culprit lesion PCI or culprit lesion only PCI. 

In a COMPLETE prespecified analysis, effect in 303 patients undergoing a pharmacoinvasive strategy was determined against 3738 patients undergoing primary PCI. Two primary end points were defined: on the one hand, cardiovascular death or new myocardial infarction and on the other hand, cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. 

The first primary end point was reduced with complete revascularization both in the patients undergoing a pharmacoinvasive strategy (2.1% vs 4.7%, HR 0.45, 95% CI, 0.21–0.97) and in patients undergoing primary PCI (2.7% vs 3.6%, HR 0.77, 95% CI, 0.62–0.95; interaction P=0.18). 


Read also: SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection.


The second primary end point was also reduced significantly with complete revascularization in patients undergoing an initial pharmacoinvasive strategy and in patients undergoing primary PCI.

Conclusion

Patients with multivessel disease with STEMI benefit from complete revascularization after treating the culprit lesion both with primary PCI and initial pharmacoinvasive strategy. 

Orignal Title: Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial.

Reference: Payam Dehghani et al. Circ Cardiovasc Interv. 2021 Aug;14(8):e010458. doi: 10.1161/CIRCINTERVENTIONS.120.010458.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...